Santhera Completes Capital Increases for Financing Arrangements
On April 30, 2021, Santhera completed the ordinary capital increase resolved on March 18, 2021, by issuing 312,000 new treasury shares for purposes of the planned restructuring of the CHF 60 million convertible bond 2017-2022 (ISIN CH0353955195) and potentially for other purposes. At the same time, 2,000,000 shares were issued out of the existing authorized capital as treasury shares. The newly created registered shares will initially be held as treasury shares in order to fulfill obligations arising from Santhera's financing instruments. After the capital increases, Santhera's share capital amounts to 26,201,136 shares.
The new shares will be listed as per May 3, 2021.
Raxone® is a trademark of Santhera Pharmaceuticals.
For further information please contact:
Disclaimer / Forward-looking statements
# # #
Great Customer Outcomes: A Balance Between Automation & Empathy
Keynote Presentation by Zoom
Exhibit Hall Open